GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Allergy Therapeutics AGY.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

1.15p

-6.50%

Close of 20 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Allergy Therapeutics — daily AGY

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Allergy Therapeutics on TradingView ↗
Market value
£70.6m
Last close × shares
Volume
5m
Shares, 20 Nov 2026

About Allergy Therapeutics

Its shares trade on LSE under the ticker AGY.L. It has been listed since 11 October 2004. In the fiscal year to 30 June 2025, it reported revenue of £55.0m and a net loss of £40.1m. At that date it held total assets of £67.5m and shareholders' equity of −£28.2m.

Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex. The company went IPO on 2004-10-11. The firm focuses on the treatment and prevention of allergy with aluminum-free products. The firm's segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World. The firm provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The firm's products include Pollinex Trees, Pollinex Grasses+Rye, Skin Prick Testing and diagnostic products. Its vaccines trade under various brand names, such as Pollinex Quattro, Polligoid and TA Graser Top. The company uses specialized systems to process the Tyrosine to form a suspension microcrystalline tyrosine (MCT) that is combined with some of its subcutaneous injected therapies.

Figures and description from our data supplier, not checked against the company's own report.

More about Allergy Therapeutics →

Latest on Allergy Therapeutics

Our reporting

Next results

4 Mar 2027

Due on 4 Mar 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Allergy Therapeutics's ticker?

Allergy Therapeutics trades as AGY.L on LSE, under ISIN GB00B02LCQ05.

What was Allergy Therapeutics's last closing price?

1.15p on 20 Nov 2026. The figure is in GBp and is never converted.

When does Allergy Therapeutics next report results?

Results are expected on 4 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.